scholarly journals Sex ratio of newborn infants born to pregnant women with severe chronic constipation

2010 ◽  
pp. 217 ◽  
Author(s):  
Andrew E. Czeizel
Keyword(s):  
Sex Ratio ◽  
Pregnant Women ◽  
Chronic Constipation ◽  
Newborn Infants ◽  
Severe Chronic Constipation

Treatment of maternal hyperthyroidism with antithyroid agents and changes in thyrotrophin and thyroxine in the newborn

1981 ◽  
Vol 97 (2) ◽  
pp. 186-195 ◽  
Author(s):  
B.-A. Lamberg ◽  
E. Ikonen ◽  
K. Teramo ◽  
G. Wägar ◽  
K. Österlund ◽  
...  
Keyword(s):  
Laboratory Test ◽  
Cord Blood ◽  
Pregnant Women ◽  
Newborn Infants ◽  
Antithyroid Drug ◽  
Clinical Indication ◽  
Antithyroid Drugs ◽  
Serum Thyroxine ◽  
Antithyroid Agents ◽  
Serum Tsh

Abstract. Eleven pregnant women with concomitant hyperthyroidism were treated with antithyroid drugs. At monthly intervals serum thyroxine (T4) and triiodothyronine (T3) were measured with radioimmunoassay, the Sephadex uptake of radioactive triiodothyronine (T3U) determined and the free T4 and T3 indices calculated (FT4I, FT3I). TSH-binding inhibiting immunoglobulins (TBII) were determined by the radiomembrane assay. Serum TSH and T4 were measured at delivery from cord blood and/or from the newborn infants some days after birth. Serum TSH was significantly elevated in one infant. There was an inadequate post-partal rise in serum T4 concentration in this child and in another who showed only a marginal elevation of TSH. The mothers of these infants were given carbimazole in doses of 30 and 25 mg/day, respectively, at the time of delivery. No significant changes were seen in other infants, the daily doses being 20 mg of carbimazole or less. There was no clinical indication of hypo- or hyperthyroidism in any of the newborn. The TBII were positive in most patients and there was a trend of normalization during treatment. No relationship between the dose of antithyroid drug and the level of TBII could be seen. During treatment the dose was adjusted according to the FT3I values. This seems to be an adequate laboratory test for this purpose.

Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications.

1985 ◽  
Vol 31 (9) ◽  
pp. 1525-1532 ◽  
Author(s):  
R Valdes
Keyword(s):  
Renal Failure ◽  
Liver Failure ◽  
Pregnant Women ◽  
Serum Proteins ◽  
Newborn Infants ◽  
Normal Subjects ◽  
Carrier Proteins ◽  
Third Trimester ◽  
Weakly Bound ◽  
Urine And Serum

Abstract Various laboratories have reported endogenous digoxin-like immunoreactive factor(s) (DLIF) in blood from patients in renal failure or liver failure, from newborn infants, and from third-trimester pregnant women. Similar immunoreactivity has been detected in amniotic fluid, in cord blood, and in urine and serum from normal subjects. The factor(s) giving rise to this immunoreactivity cross react with antibodies used in many currently available immunoassays for digoxin, sometimes causing apparent digoxin concentrations exceeding the therapeutic range obtained for exogenous digoxin, with consequent errors in measurement and in subsequent clinical interpretation of digoxin results. Here, I summarize findings in our laboratory and those of others. DLIF evidently exist in three states in serum: tightly protein-bound, weakly protein-bound, and unbound (free). In normal subjects, greater than 90% of the total DLIF in serum is tightly but reversibly bound to serum proteins and is not readily detectable by direct measurement of digoxin in serum with conventional immunoassays. However, there seems to be a redistribution of the more weakly bound and unbound components in patients with renal failure, pregnant women, and newborns. The increased values detected in these groups are ascribable to increased amounts of weakly bound and unbound DLIF rather than to increased total DLIF. Carrier proteins may play a prominent role in the transport of these factors in blood. I discuss the potential physiological and pharmacological implications of detecting endogenous immunoreactive factors that cross react with antibodies to drugs.

scholarly journals Obstructive Uropathy in a Child with Severe Chronic Constipation

2012 ◽  
Vol 21 (3) ◽  
pp. 209-212
Author(s):  
Veena Logarajah ◽  
Kong Boo Phua ◽  
Te Lu Yap ◽  
Christina Ong
Keyword(s):  
Chronic Constipation ◽  
Obstructive Uropathy ◽  
Severe Chronic Constipation

PS2-003. Corrective effects of recombinant alpha2-interferon (Viferon®) therapy in pregnant women with urogenital infections on the innate immunity status of newborn infants

Cytokine ◽  
2011 ◽  
Vol 56 (1) ◽  
pp. 64-65
Author(s):  
E.N. Vyzhlova ◽  
E.V. Dmitrieva ◽  
V.V. Malinovskaya ◽  
I.I. Bocharova ◽  
S.V. Novikova ◽  
...  
Keyword(s):  
Innate Immunity ◽  
Pregnant Women ◽  
Newborn Infants ◽  
Urogenital Infections

EXCRETION OF 15α-HYDROXYOESTRIOL AND OESTRIOL IN URINE OF NEWBORN INFANTS AND IN MATERNAL URINE BEFORE AND AFTER DELIVERY

1972 ◽  
Vol 52 (1) ◽  
pp. 119-128 ◽  
Author(s):  
JORMA HEIKKILÄ
Keyword(s):  
Pregnant Women ◽  
Linear Function ◽  
Newborn Infant ◽  
Newborn Infants ◽  
Urine Samples ◽  
Maternal Urine ◽  
Before And After

SUMMARY The amounts of oestriol and 15α-hydroxyoestriol (oestetrol) were determined in 24-h urine samples collected from pregnant women before and after delivery. In addition, the concentrations of these oestrogens were estimated in the urine of the newborn infants born to these mothers. The excretion of both these oestrogens decreased exponentially in maternal urine after delivery, the rate of decrease being significantly slower for oestetrol. The concentration of oestriol and oestetrol in the urine of the newborn infants also fell rapidly after delivery, the reduction being a linear function of time. The concentration of oestetrol in the urine of the newborn infant was relatively high in comparison to that of oestriol, and during the first day of life was the same as in maternal urine before delivery.

Misoprostol is effective treatment for patients with severe chronic constipation

1994 ◽  
Vol 39 (5) ◽  
pp. 929-933 ◽  
Author(s):  
Edy E. Soffer ◽  
Amanda Metcalf ◽  
Janice Launspach
Keyword(s):  
Effective Treatment ◽  
Chronic Constipation ◽  
Severe Chronic Constipation

scholarly journals An Analysis of 38 Pregnant Women With COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes

2020 ◽  
Vol 144 (7) ◽  
pp. 799-805 ◽  
Author(s):  
David A. Schwartz
Keyword(s):  
Pregnant Women ◽  
Pregnancy Outcomes ◽  
Viral Infections ◽  
Clinical Laboratory ◽  
Newborn Infants ◽  
Public Health Problem ◽  
Obstetric Outcomes ◽  
Maternal Fetal Transmission ◽  
Novel Coronavirus ◽  
Coronavirus Infections

The emergence of a novel coronavirus, termed SARS-CoV-2, and the potentially life-threatening respiratory disease that it can produce, COVID-19, has rapidly spread across the globe, creating a massive public health problem. Previous epidemics of many emerging viral infections have typically resulted in poor obstetric outcomes including maternal morbidity and mortality, maternal-fetal transmission of the virus, and perinatal infections and death. This article reviews the effects of 2 previous coronavirus infections—severe acute respiratory syndrome (SARS) caused by SARS-CoV and Middle East respiratory syndrome (MERS) caused by MERS-CoV—on pregnancy outcomes. In addition, it analyzes literature describing 38 pregnant women with COVID-19 and their newborns in China to assess the effects of SARS-CoV-2 on the mothers and infants, including clinical, laboratory, and virologic data, and the transmissibility of the virus from mother to fetus. This analysis reveals that unlike coronavirus infections of pregnant women caused by SARS and MERS, in these 38 pregnant women COVID-19 did not lead to maternal deaths. Importantly, and similar to pregnancies with SARS and MERS, there were no confirmed cases of intrauterine transmission of SARS-CoV-2 from mothers with COVID-19 to their fetuses. All neonatal specimens tested, including placentas in some cases, were negative by RT-PCR for SARS-CoV-2. At this point in the global pandemic of COVID-19 infection there is no evidence that SARS-CoV-2 undergoes intrauterine or transplacental transmission from infected pregnant women to their fetuses. Analysis of additional cases is necessary to determine if this remains true.

Sign in / Sign up

Export Citation Format

Share Document